Navigation Links
China Kanghui Holdings Reports Third Quarter 2011 Financial Results
Date:11/9/2011

ngsConsolidated Statements of OperationsExpressed in thousands, except share and per share dataThree Months Ended September 30,Nine Months Ended September 30,2010201120102011RMB

RMB

US$RMB

RMB

US$Unaudited

Unaudited

UnauditedUnaudited

Unaudited

UnauditedNet revenue63,599

80,659

12,646170,469

230,392

36,123Cost of revenue

(17,898)

(22,145)

(3,472)(51,326)

(65,113)

(10,209)Gross profit45,70158,5149,174119,143165,27925,914Operating expensesSelling expenses

(5,470)

(8,261)

(1,295)(16,957)

(26,999)

(4,233)General and administrative expenses

(6,150)

(10,664)

(1,672)(21,009)

(35,212)

(5,521)Research and development costs

(1,726)

(3,218)

(505)(3,758)

(6,519)

(1,022)Operating income32,35536,3715,70277,41996,54915,138Interest income

1,207

6,295

9871,857

10,543

1,653Government grants

330

-

-360

3,190

500Other income

34

941

147478

1,934

303Other expenses

(36)

(970)

(152)(313)

(1,878)

(294)Foreign exchange loss

(2,900)

(2,783)

(436)(3,081)

(8,124)

(1,274)Income before income taxes30,99039,8546,24876,720102,21416,026Income tax expense

(4,342)

(11,108)

(1,742)(4,542)

(23,869)

(3,742)Net income26,64828,7464,50672,17878,34512,284Net loss attributable to non-controlling interests

-

139

22-

388

61Net income attributable to China Kanghui Holdings26,64828,8854,52872,17878,73312,345Accretion of redeemable convertible preferred shares:Series A

(1,483)

-

-(7,572)

-

-Series B

(10,977)

-

-(54,988)

-

-Series B-1

(567)

-

-(2,844)


'/>"/>
SOURCE China Kanghui Holdings
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
(Date:7/29/2014)... (NYSE: CVD ) today reported results for ... was $639 million, representing 8.0% growth from the second ... reported earnings of $0.29 per diluted share in the ... diluted share of $0.95, up 21.5% over the second ... charges totaling $52.6 million, or $0.61 per share, and ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24
(Date:7/29/2014)... SC (PRWEB) July 29, 2014 During his ... L. Bruce, DMD & Associates, has had a steady stream ... about dentistry. These students have now gone on to dental ... practices, proving that the shadowing program helps college students find ... Dr. Bruce has given them the chance to see a ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
(Date:7/29/2014)... app that helps headache sufferers to record the severity ... part of a Griffith research study. , A new ... looks at coping with their triggers and is being ... Behaviorial Basis of Health program. , He has developed ... the triggers of their headaches called Learning to Cope ...
(Date:7/29/2014)... Bret Busacker , a partner in ... been appointed to the Board of Directors for the ... an experienced business attorney with a focus on employee ... a wide spectrum of topics regarding equity and incentive ... concerns. His clients include public and private businesses, governmental ...
(Date:7/29/2014)... 29, 2014 Child abuse law firm Steinger, ... this week. The scholarship will help future lawyers who want ... families. , Steinger, Iscoe and Greene lawyers work continuously to ... attorneys to do the same. More than 6 million children ... the nonprofit Childhelp (retrieved 7/22/2014). , “This is ...
Breaking Medicine News(10 mins):Health News:Arthur Bruce Dental Helps College Students 2Health News:Caring for donors 2Health News:Caring for donors 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2
... with an eye-alignment disorder called infantile esotropia have ... up after corrective surgery, reports a study in ... Pediatric Ophthalmology and Strabismus). , Led by James ... Southwest Texas, Dallas, the researchers assessed developmental milestones ...
... highest-risk professions for ergonomic injury, according to a new ... indicates that interpreting causes more physical stress to the ... assembly line work. It also found a direct link ... of the interpreter and an increase in the risk ...
... reliability, improves information flow, facilitates documentation and, compliance, and ... ... outcomes., ... release of an enhanced NaviCare(R) WatchChild(R),solution, following receipt of marketing ...
... to Focus on Healthcare, Trade and the Economy, ... and think tanks can take part in National Small,Business ... the,agency,s premier annual event., These public policy forums ... business and the economy:, WHO:, Secretary Michael ...
... no cost to Twin Cities, consumers, the bi-monthly magazine,published in partnership ... content written and edited by the most experienced health ... journalists in ... Twin Cities,residents will soon have a unique health and wellness resource ...
... A new hybrid hearing aid/cochlear implant device designed for ... UT Southwestern Medical Center otolaryngologists, as part of a multisite, ... System, or EAS, is already used in Europe, but not ... a population currently falling through the cracks borderline cases ...
Cached Medicine News:Health News:Infantile esotropia linked to developmental delays 2Health News:RIT study: Sign language interpreters at high ergonomic risk 2Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:Live Webcast of SBA's National Small Business Week Policy Forums Scheduled 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 3Health News:UT Southwestern testing new hybrid hearing device combining advantages of hearing aids, implants 2
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
... Retrograde Humeral Nail enables fixation of humeral ... that may be associated with antegrade nailing. ... and distal interlocking using a nail-mounted targeting ... interlocking with the patient in the prone ...
Medicine Products: